Stephen Kimura, MD
Allergy & Immunology · Pensacola, FLNPI 1891776563
Payments from drug & device makers
Across 736 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$2K
- Sanofi$2K
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Novartis$872
- plus $6K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 80 | $2,172 |
| AstraZeneca | 120 | $2,160 |
| Sanofi | 72 | $1,600 |
| GSK | 114 | $1,599 |
| Takeda Pharmaceuticals U.S.A., Inc. | 73 | $1,469 |
| Novartis | 15 | $872 |
| Amgen(2 entities) | 30 | $756 |
| Genentech USA, Inc. | 40 | $739 |
| Octapharma USA, Inc. | 13 | $568 |
| Grifols USA, LLC | 25 | $567 |
| Optinose US, Inc. | 25 | $448 |
| Kaleo, Inc. | 16 | $336 |
| CSL Behring | 11 | $331 |
| Pfizer | 14 | $273 |
| AbbVie | 11 | $261 |
| Blueprint Medicines Corporation | 11 | $238 |
| Shire North American Group Inc | 12 | $234 |
| Boehringer Ingelheim | 11 | $219 |
| Biocryst US Sales Co., LLC | 9 | $209 |
| Incyte Corporation | 6 | $125 |
| Pharming Healthcare, Inc. | 6 | $111 |
| Aimmune Therapeutics, Inc. | 4 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Lilly USA, LLC | 2 | $47 |
| Hikma Pharmaceuticals USA | 3 | $46 |
| LEO Pharma Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Merck | 2 | $34 |
| ADMA Biomanufacturing LLC | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $26 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Organon | 1 | $13 |
| Alk-abello, Inc | 1 | $12 |
How this compares
$15,765 in reported general payments places this provider in the 70th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Pensacola
- Thomas WestbrookPensacola$925K
- Jaime LandmanAventura$3.9M
- Ileana RodicioMiami$3.8M
- Jose CarpioMiami$3.6M
- Michael KohenDaytona Beach$3.6M
- Thomas CasaleTampa$1.7M
- Dennis LedfordTampa$1.4M
- Ronald SaffTallahassee$1.2M
- Shahnaz FattehPlantation$1M
- Seong ChoTampa$969K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.